Moderna, Inc.
MRNA Healthcare Biotechnology NASDAQ
$50.73
$-2.12 (-4.01%)
Open: $53.38 | High: $53.49 | Low: $50.57 | Prev Close: Prev Close: $52.85
Market Cap: $20.12B
Volume: 4.3M | Avg: 8.6M
Last updated: April 24, 2026 at 08:03 PMFeatured In
This stock appears in the following dashboards:
Options Activity for MRNA
Options Screener Data
| Type | Strike | Expiration | Premium | Premium Yield | Call Vol | Put Vol | P/C Ratio | Rating |
|---|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A% | N/A | N/A | N/A | N/A/10 |
Puts/Calls Activity
| Type | Strike | Expiration | Premium | Volume | ROI % | Breakeven | Delta |
|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A | N/A% | $N/A | N/A |
Investment Rating
Sell
Overall Score: 40/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 440
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | -6.99 |
| P/B Ratio | 2.30 |
| P/S Ratio | 10.35 |
| EPS | $-7.26 |
| Beta | 1.34 |
| Shares Outstanding | 396.59M |
| 52-Week High | $59.55 |
| 52-Week Low | $22.28 |
| SMA 50 | $51.35 |
| SMA 200 | $35.27 |
| Next Earnings | May 01, 2026 12:30 PM ET |
Financial Ratios
| Gross Margin | 14.1% |
| Operating Margin | -158.2% |
| Net Margin | -145.2% |
| ROE | -30.1% |
| ROA | -22.9% |
| Debt/Equity | 0.22 |
| Current Ratio | 3.29 |
| Quick Ratio | 3.22 |
Balance Sheet
| Total Assets | $12.34B |
| Total Liabilities | $3.69B |
| Total Equity | $8.65B |
|
|
|
| Cash | $2.60B |
| Total Debt | $1.92B |
| Net Debt | $-679,000,000 |
Income Statement
| Revenue | $1.94B |
| Gross Profit | $1.08B |
| Operating Income | $-3,074,000,000 |
| Net Income | $-2,822,000,000 |
|
|
|
| EBITDA | $-2,553,000,000 |
| Revenue/Share | $4.96 |
Cash Flow
| Operating CF | $-1,873,000,000 |
| CapEx | $192.00M |
| Free Cash Flow | $-2,065,000,000 |
|
|
|
| Book Value/Share | $22.07 |
| Tangible Book/Share | $22.07 |
| Equity/Share | $22.07 |
Technical Indicators
| RSI (14) | 55.00 Neutral |
| MACD |
0.80
Signal: 0.72
|
| Volatility | 55.60% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | +54.71% |
| Sharpe Ratio | 1.01 Good |
| Volatility (Ann.) | 72.77% High Risk |
| MRNA (1Y) | +54.71% |
| S&P 500 (1Y) | +14.41% |
| Alpha (Excess Return) | +40.3% |
Sector Comparison (Healthcare)
| Metric | MRNA | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | -6.99 | 26.92 | 2% |
| P/B Ratio | 2.3 | -21.06 | 36% |
| ROE (%) | -30.15% | -9.27% | 10% |
| Net Margin (%) | -145.24% | 12.60% | 0% |
| Stock Score | 440 | 541.0 | 12% |
| 1Y Return (%) | +54.71 % | +4.11 % | 96% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | $50.73 | $53.94 | $53.85 | $52.91 | $51.46 | $35.35 | 55.00 | 0.80 | 55.60% | 618335 | Weak Short | Bullish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the MRNA stock
News Sentiment
| Ticker | Headline | Sentiment | Source | URL |
|---|---|---|---|---|
| MRNA | CureVac sues Moderna for patent infringement over COVID-19 vaccines | Neutral | reuters.com | Read More |
| MRNA | Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release | Negative | zacks.com | Read More |
| MRNA | Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing | Neutral | zacks.com | Read More |
| MRNA | European Commission Approves MRNA's COVID-19-Influenza Combo Shot | Neutral | zacks.com | Read More |
| MRNA | Moderna starts late-stage trial of bird flu vaccine in US, UK | Neutral | reuters.com | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-02 | Mock James M | officer: Chief Financial Officer | SELL | 703 | $50.03 | $35171 |
Company Information
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
| CEO | Stéphane Bancel |
| Employees | 5800 |
| Country | US |
| IPO Date | 2018-12-07 |
| Exchange | NASDAQ |
| Website | https://www.modernatx.com |
| Sector | Healthcare |
| Industry | Biotechnology |
Similar Stocks (Healthcare - Biotechnology)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category